文献速递胸部肿瘤

阿替利珠单抗用于切除后IB-IIIA期非小细胞肺癌化疗后的五年生存结局(IMpower010):一项开放标签、随机、III期试验

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
PubMed 文献 · J Clin Oncol · 2025-05-30

IMpower010研究显示,在完全切除的IB-IIIA期非小细胞肺癌患者中,铂类辅助化疗后使用阿替利珠单抗对比最佳支持治疗,中位随访≥5年时,II-IIIA期PD-L1肿瘤细胞≥1%人群的DFS HR为0.70(95%CI 0.55-0.91),OS HR为0.77(95%CI 0.56-1.06),未报告新的安全性信号。

要点

  • IB-IIIA期完全切除NSCLC铂类化疗后,阿替利珠单抗对比BSC的DFS最终分析:ITT人群HR 0.85(95%CI 0.71-1.01;P=0.07),未达统计学显著。
  • II-IIIA期PD-L1 TC≥1%人群DFS HR 0.70(95%CI 0.55-0.91),OS HR 0.77(95%CI 0.56-1.06)。
  • II-IIIA期PD-L1 TC≥50%且无EGFR/ALK异常人群(n=209)DFS HR 0.49(95%CI 0.32-0.75),OS HR 0.44(95%CI 0.26-0.74)。

核心结论

  • IMpower010是首个报告≥5年随访生存结局的研究,继续显示在切除后II-IIIA期PD-L1选择的人群中,辅助化疗后阿替利珠单抗对比BSC具有获益。

研究设计与样本

  • 开放标签、随机、III期试验(IMpower010,NCT02486718),完全切除的IB-IIIA期NSCLC患者铂类化疗后随机分配至阿替利珠单抗(1200 mg 每3周一次,共16周期)或BSC。
  • 意向治疗人群n=1005,全部随机II-IIIA期人群n=882,II-IIIA期PD-L1 TC≥1%人群n=476,II-IIIA期PD-L1 TC≥50%人群n=229,II-IIIA期PD-L1 TC≥50%且无EGFR/ALK异常人群n=209。
  • 数据截止日期为2024年1月26日,随访≥5年,报告DFS最终分析、第二次OS中期分析及安全性。

主要发现

  • DFS分层HR(95%CI):ITT人群0.85(0.71-1.01;P=0.07),全部随机II-IIIA期人群0.83(0.69-1.00),II-IIIA期PD-L1 TC≥1%人群0.70(0.55-0.91)。
  • OS分层HR(95%CI):ITT人群0.97(0.78-1.22),全部随机II-IIIA期人群0.94(0.75-1.19),II-IIIA期PD-L1 TC≥1%人群0.77(0.56-1.06)。
  • II-IIIA期PD-L1 TC≥50%人群未分层HR(95%CI):DFS 0.48(0.32-0.72),OS 0.47(0.28-0.77)。
  • II-IIIA期PD-L1 TC≥50%且无EGFR/ALK异常人群未分层HR(95%CI):DFS 0.49(0.32-0.75),OS 0.44(0.26-0.74)。
  • 未报告新的安全性信号。

关键数值与推荐

  • DFS分层HR在II-IIIA期PD-L1 TC≥1%人群为0.70(95%CI 0.55-0.91),在ITT人群为0.85(95%CI 0.71-1.01;P=0.07)。
  • OS分层HR在II-IIIA期PD-L1 TC≥1%人群为0.77(95%CI 0.56-1.06),在ITT人群为0.97(95%CI 0.78-1.22)。
  • II-IIIA期PD-L1 TC≥50%人群DFS未分层HR 0.48(95%CI 0.32-0.72),OS未分层HR 0.47(95%CI 0.28-0.77)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMpower010 (ClinicalTrials.gov identifier: NCT02486718) previously showed that atezolizumab improved disease-free survival (DFS) versus best supportive care (BSC) after adjuvant chemotherapy in patients with resected non-small cell lung cancer (NSCLC). We report DFS final analysis, second overall survival (OS) interim analysis, and safety with a ≥5-year follow-up. Patients with completely resected stage IB-IIIA NSCLC were randomly assigned to atezolizumab (1,200 mg once every 3 weeks, 16 cycles) or BSC after platinum-based chemotherapy. At clinical cutoff (January 26, 2024), stratified hazard ratios (HRs; 95% CI) for DFS were 0.85 (95% CI, 0.71 to 1.01; P = .07) in the intention-to-treat (n = 1,005), 0.83 (95% CI, 0.69 to 1.00) in the all-randomized stage II-IIIA (n = 882), and 0.70 (95% CI, 0.55 to 0.91) in stage II-IIIA PD-L1 tumor cell (TC) ≥1% (n = 476) populations. Stratified HRs (95% CI) for OS were 0.97 (95% CI, 0.78 to 1.22), 0.94 (95% CI, 0.75 to 1.19), and 0.77 (95% CI, 0.56 to 1.06), respectively. The unstratified HRs (95% CI) in the stage II-IIIA PD-L1 TC ≥50% population (n = 229) were 0.48 (95% CI, 0.32 to 0.72) for DFS and 0.47 (95% CI, 0.28 to 0.77) for OS, and the unstratified HRs in the stage II-IIIA PD-L1 TC ≥50% without EGFR/ALK alterations (n = 209) population were 0.49 (95% CI, 0.32 to 0.75) and 0.44 (95% CI, 0.26 to 0.74). No new safety signals were reported. IMpower010 is the first study to report survival outcomes with a ≥5-year follow-up and continued to show benefit with atezolizumab versus BSC after adjuvant chemotherapy in patients with resected stage II-IIIA PD-L1-selected NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Felip E, Altorki N, Zhou C, et al. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. J Clin Oncol. 2025. PMID: 40446184. doi:10.1200/JCO-24-01681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。